TMCnet News
Schrödinger Appoints Geoffrey Porges as Chief Financial OfficerSchrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry. As Schrödinger's CFO, he will lead all aspects of the company's financial operations and investor relations and corporate affairs activities. He will also oversee business development and strategic planning for the company's proprietary pharmaceuticals and biopharmaceutical collaborations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005061/en/ Schrödinger, whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. (Photo: Business Wire) "Geoff is a proven leader in the biopharmaceutical and investment industries and has been one of the most respected analysts covering biopharma," said Ramy Farid, Ph.D., chief executive officer at Schrödinger. "His deep expertise in capital allocation and corporate strategy will play a key role in driving the anticipated growth of the company." "After over 30 years of investment Schrödinger's physics-based drug discovery platform has been widely validated and is the leading technology for predictive modeling and drug design in biopharma," said Dr. Porges. "The company's balance sheet and revenue outlook are very strong and there are many opportunities to expand the company's current portfolio of collaborative and internal programs, and software partnerships. I'm excited to contribute to the next chapter of Schrödinger's remarkable history." Dr. Porges joins Schröinger from SVB Securities, where he was most recently vice chairman. From 2015 until 2022, Dr. Porges was senior managing director, director of therapeutics research and senior research analyst at SVB Securities and at Leerink prior to its acquisition by SVB Securities. In that capacity, he led the Leerink/SVB therapeutics research team and personally provided research coverage for established and emerging diversified biopharmaceutical companies. Prior to joining SVB Securities, he was the biotechnology research analyst at Alliance Bernstein for 13 years. Earlier in his career, he held executive positions at BTG plc and Merck, including leading the commercialization of Merck's human vaccines. Dr. Porges earned his medical degree from the University of Sydney and trained in pediatric and internal medicine in Australia. He is also a graduate of Harvard Business School where he was a Baker Scholar.
About Schrödinger
Founded in 1990, Schrödinger has over 700 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com follow us on LinkedIn and Twitter, or visit our blog, Extrapolations.com.
Cautionary Note Regarding Forward-Looking Statements
View source version on businesswire.com: https://www.businesswire.com/news/home/20220818005061/en/ |